Madrid, 26/03/2012 Marta Gómez Quintanilla IMI & Health Spanish Representative EU s R&D Framework Programme Department

Transcription

1 Madrid, 26/03/2012 Marta Gómez Quintanilla IMI & Health Spanish Representative EU s R&D Framework Programme Department 1 (27/03/2012)

2 Índice Spanish participation & results 1st call & 2nd call statistics 3rd & 4th call overview Future 2 (27/03/2012)

3 Índice Spanish participation & results 1st call & 2nd call statistics 3rd & 4th call overview Future 3 (27/03/2012)

4 IMI 2008 PRELIMINARY DATA Projects IMI 2008 Financed with ES, nº (% total) Coordinated ES, nº (% total) 12 (80%) 0 (0%) Entities results Funding Spanish entities in funded projects (% del total) SMEs Millions % UE-27 (% total) 17 (8,1%) 3 7 6,90% (6,4%) Spanish position (funding) 5ª AI 40,4% AAPP 5,3% Madrid 21,1% Murcia 4,3% EMP 7,3% UNIV 5,4% Tipo de Entidad CPI 41,6% CCAA Cataluña 74,7% 4 (27/03/2012)

5 IMI 2008 Institut Catala De Ciencies Cardiovasculars Fundacion Imim Fundacio Institut Catala De Farmacologia Institut D`investigacions Biomediques August Pi I Sunyer Agencia Estatal Consejo Superior De Investigaciones Cientificas Agencia Española De Medicamentos Y Productos Sanitarios Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III Fundación Centro Español De Investigación Farmacoepidemiológica Universidad De Murcia Lead Molecular Design Sl Chemotargets Sl España Universidad De Barcelona España Universidad Autonoma De Barcelona España Universidad Pompeu Fabra Almirall Sa Laboratorios Del Dr Esteve, S.A. Neuroscience Technologies S.L.P Lab. Esteve Almirall Entidades 5 (27/03/2012)

6 IMI 2009 PRELIMINARY DATA IMI 2009 Projects Entities results Funding Financed with ES, nº (% total) Coordinated ES, nº (% total) Spanish entities in funded projects (% del total) SMEs Millions % UE-27 (% total) 3 (37,5%) 0 (0%) 6(4,4%) 0 1,8 2,34% (2,2%) Spanish position (funding) 10ª CPI 72,9% UNIV 27,2% Galicia 18% Madrid Navarra 9% 0% Cataluña 36% Consorci Mar Parc De Salut De Barcelona Fundacion Centro Nacional De Investigaciones Oncologicas Carlos III Universidad De Santiago De Compostela Agencia Estatal Consejo Superior De Investigaciones Cientificas Universidad De Navarra Laboratorios Del Dr Esteve, S.A. Tipo de Entidad CCAA Entidades 6 (27/03/2012)

7 Calls 1 & 2: consolidated figures Call 1 Call 2 Total Projects EFPIA Companies Academic teams SME teams Patients organisat Total Budget (M ) IMI 4th Call for Proposals, (27/03/2012) June 2011

8 Calls 1 & 2: consolidated figures /ES Participation Call 1 Call 2 Total Projects 15 /12 8 /3 23/15 EFPIA Companies 21/2 21/1 23/2 Academic teams 195/14 103/5 298/19 SME teams 24/3 23/0 47/3 Patients organisat. 9/0 2/0 11/0 Total Budget (M ) IMI 4th Call for Proposals, June (27/03/2012) Slide modified

9 Spanish results in Health research Call M (Spain) (%EU-27) FP7-HEALTH-2011-single-stage 14,7 10,3% FP7-HEALTH-2011-two-stage 37,6 8,3% IMI_Call_2008_1 7,0 6,9% IMI_Call_2009_1 1,8 2,3% Total 61,2 7,9% Year M (Spain) %UE ,0 4,2% ,1 6,4% ,7 5,5% ,0 5,4% ,2 7,9% Total 177,1 6,0% 9 (27/03/2012) Fuente:

10 More information on results Fuente: 10 (27/03/2012)

11 11 (27/03/2012)

12 Calls 1st to 3rd 12 (27/03/2012)

13 Calls 1st to 3rd 13 (27/03/2012)

14 Calls 1st to 3rd 14 (27/03/2012)

15 Estimated results for Spain 1st Call nd Call rd Call 2010 Estimated, no consolidated 4th Call Estimated, no consolidated TOTAL Estimated,, no consolidated IMI funding 110 million 80 million 114 million 105 million EFPIA contribution (as in call text) million + 80 million million million = 242 million = 160 million = 228 million = 210 million = 840 Call topics (7) 43 Expressions of Interest Participants EoIs/topic 7,4 13,7 4,6 8,9 8,6 Funded Projects ? 9? Success rate 11,2% 7,3% 21,9% 11,3% 11,6% ES in Funded Projects (no EFPIA) 9 3 2nd stage est. 2nd stage est. ES participations (no EFPIA) / ES entities (no EFPIA) 15 (3 SMEs) 5 (0 SMEs) 4/3 (0 SMEs) 2 (1 SME) 26 (4 SMEs) 15 (27/03/2012)

16 Índice Spanish participation & results 1st call & 2nd call statistics 3rd & 4th call overview Future 16 (27/03/2012)

17 SRA 17 (27/03/2012)

18 SRA Old priorities, still there (2008): Safety Sciences Increasing Practicability of Biomarkers and Biobanks Coping with Regulatory and Legal Hurdles Knowledge Management Science Communication Neuro-psychiatric Disorders/Brain Disease Inflammatory Diseases Cancer Metabolic Diseases including cardiovascular diseases Infectious Diseases 18 (27/03/2012)

19 SRA New priorities (2011): Pharmacogenetics and taxonomy of human diseases; Rare diseases and stratified therapies; Systems approaches in drug research; Beyond high throughput screening - pharmacological interactions at the molecular level; Active Pharmaceutical Ingredient (API) technology (drug compound development); Advanced formulations; Stem cells for drug development and toxicity screening; Integration of imaging techniques into drug research. 19 (27/03/2012)

20 Sumary existing and new priorities 20 (27/03/2012)

21 Call definition -> SRG Governance Building an IMI project (1) IMI 4th Call for Proposals, June 2011 Call definition and launch IMI Research Agenda (multi-annual plan) Contains EFPIA priorities Advice of Scientific Committee (SC) Consultation of States Representatives Group (SRG) Approval by IMI Governing Board Annual scientific priorities Proposed by EFPIA Consultation of SC and SRG Approval by IMI Governing Board Definition of research topics Proposed by EFPIA Detailed description of research topics EFPIA + IMI Executive Office Consultation of SC and SRG Approval by IMI Governing Board Launch of the Call IMI Executive Office 21 (27/03/2012) IMI 4th Call for Proposals, June 2011

22 SRA topics 22 (27/03/2012)

23 SRA topics 23 (27/03/2012)

24 SRA topics 24 (27/03/2012)

25 SRA topics 25 (27/03/2012)

26 SRA topics 26 (27/03/2012)

27 Budget The Innovative Medicines Initiative (IMI): the largest PPP in life sciences R&D IMI 4th Call for Proposals, June (27/03/2012)

28 Budget scenario: IMI-JU + EFPIA M * estimated budget, tbd 2010* 2011* 2011/2012** 2012** TOTAL 28 (27/03/2012) ** simulation in which the remaining budget is divided between two years, tbd Call 1033 EFPIA Several calls/year!! IMI JU ~ 600M IMI JU

29 TBC 29 (27/03/2012)

30 IMI OFFICE: ORGANISATIONAL CHART 30 (27/03/2012)

31 CDTI Contact details CDTI Contact Person Dpto. Progr. Marco de I+D. Dir. Programas Innovadores Globales Dpto. Biotecnología, Salud y Agroalimentación. Dirección Mercados Innovadores Globales Marta Gómez Quintanilla Representante Salud e IMI Carolina Carrasco NCP- HEALTH Pilar Sanz Mª Pilar de Miguel NCP-NMP marta.gomez@cdti.es carolina.carrasco@cdti.es mariapilar.sanz@cdti.es mariapilar.demiguel@cdti.es (27/03/2012)

32 LINKS Mailing List Agenda Info FP7 & IMI 32 (27/03/2012)

33 Last remarks Strategy Suport NCPs, IMI Executive Office, support offices, Plat. Med. Inn., Asebio, Nanomed, etc. Good luck! 33 (27/03/2012)

34 Marta Gómez Quintanilla Spanish Representative - HEALTH Spanish Representative IMI Spanish MB Member - JPND Ph: / 00 marta.gomez[at]cdti.es (27/03/2012)